foscarnet has been researched along with everolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agut, H; Aït-Arkoub, Z; Autran, B; Boutolleau, D; Burrel, S; Carcelain, G; Conan, F; Deback, C; Gandjbakhch, I; Varnous, S | 1 |
2 review(s) available for foscarnet and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Management of multidrug-resistant CMV infection in immunocompromised patients: case report of a heart-transplant recipient and review of the literature.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Disease Management; Drug Resistance, Viral; Everolimus; Female; Foscarnet; Ganciclovir; Heart Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infant; Male; Middle Aged; Valganciclovir; Viral Load | 2015 |